Formoterol/budesonide pressurized metered-dose inhaler: a guide to its use in chronic obstructive pulmonary disease


    loading  Checking for direct PDF access through Ovid

Abstract

The use of a single pressurized metered-dose inhaler (pMDI) containing both formoterol (a long-acting β2-selective adrenoreceptor agonist) and budesonide (an inhaled corticosteroid) is an effective, convenient and well- tolerated option for the treatment of adults with symptoms of moderate to severe chronic obstructive pulmonary disease (COPD) and a history of recurrent COPD exacerbations. Two inhalations of formoterol/budesonide pMDI 6/200 μg twice daily provided rapid and durable improvements in lung function, as well as improvements in COPD control, COPD symptoms and health status outcomes, in clinical trials in patients with moderate to very severe COPD.

    loading  Loading Related Articles